New Study Offers Nuanced Look at Weight Regain After Stopping GLP-1 Meds

Cleveland Clinic research suggests significant weight regain isn't inevitable, highlighting the importance of continued healthcare engagement.

Mar. 21, 2026 at 3:05pm

Got story updates? Submit your updates here. ›

A new study from the Cleveland Clinic analyzing data from nearly 8,000 adults found that patients experienced minimal weight regain - averaging just 0.5% after one year - after discontinuing GLP-1 medications like Ozempic and Wegovy. The study suggests that many patients don't simply stop treatment, but rather transition to alternative treatments or lifestyle programs, which may explain the difference from previous clinical trial findings.

Why it matters

Millions have turned to GLP-1 medications for weight loss, but concerns have been raised about a potential 'rebound effect' with rapid weight regain after stopping the injections. This new real-world data provides a more nuanced picture, highlighting the importance of continued engagement with the healthcare system to maintain weight loss success.

The details

The Cleveland Clinic study found that approximately 27% of patients transitioned to different obesity medications, while another 20% restarted their original GLP-1 medication after resolving issues like insurance coverage or side effects. A further 14% engaged in intensive lifestyle modification programs. This suggests that many patients don't simply stop treatment, but rather shift to alternative approaches, which may explain the lower rates of weight regain observed.

  • The Cleveland Clinic study analyzed data from nearly 8,000 adults.
  • Patients experienced an average weight regain of just 0.5% after one year.

The players

Cleveland Clinic

A nonprofit academic medical center that conducted the study on weight regain after stopping GLP-1 medications.

Dr. Hamlet Gasoyan

The lead author of the Cleveland Clinic study.

Ozempic

A GLP-1 medication used for weight loss.

Wegovy

A GLP-1 medication used for weight loss.

Zepbound

A GLP-1 medication used for weight loss.

Got photos? Submit your photos here. ›

What they’re saying

“Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials.”

— Dr. Hamlet Gasoyan, Lead study author

What’s next

Researchers emphasize the importance of continued engagement with the healthcare system, whether through alternative prescriptions or structured lifestyle support, to maintain weight loss success.

The takeaway

This study highlights the importance of considering real-world outcomes beyond the controlled environment of clinical trials, and the potential benefits of a more holistic approach to weight management that includes medication, lifestyle changes, and personalized care.